AKT1 and neoplasm: In a context of permanent ligand-based activation (as is occurring in the tumor), the inhibitors join forces to reduce several malignant properties of the TNBC cells including survival, AKT activation, cell growth, invadopodia formation, matrix proteolysis, and, importantly, migration and invasion.